Meralys Duo (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride selectively stimulates alpha‑adrenergic receptors on the blood vessels of the nasal lining. This causes vasoconstriction, which limits blood flow, decreases mucosal edema, and opens the nasal passages, providing rapid relief of congestion.

The appropriate dose of Meralys Duo is determined by a qualified healthcare professional. Typically, the prescriber will advise the number of sprays per nostril and the maximum duration of treatment, which should not exceed the recommended limit to avoid rebound congestion.

Safety data for Xylometazoline Hydrochloride in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their healthcare provider before using Meralys Duo to weigh potential benefits against any unknown risks.

To place an order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide institutional or trade credentials. GNH India’s team will verify the information, then respond with pricing, availability, shipping details, and any necessary import documentation.

Meralys Duo contains Xylometazoline Hydrochloride, an imidazoline‑type decongestant, which typically provides rapid onset of action similar to oxymetazoline. Both agents act via alpha‑adrenergic vasoconstriction, but formulation differences and individual patient response may influence choice. Clinical guidelines recommend limiting use of any topical decongestant to a few days.

Store Meralys Duo below 25 °C in its original packaging, protecting it from moisture, direct sunlight, and extreme heat. Keep the container tightly closed when not in use and keep out of reach of children.

Meralys Duo is administered intranasally. The user tilts the head slightly forward, inserts the spray tip into one nostril, and delivers the prescribed number of sprays while breathing in gently. The same procedure is repeated for the other nostril if directed by the prescriber.

Serious risks include severe nasal bleeding, allergic reactions such as rash or swelling, and systemic effects like hypertension or rapid heart rate. If any of these occur, discontinue use immediately and seek medical attention.

Meralys Duo should be avoided by individuals with known hypersensitivity to Xylometazoline or any component of the formulation, children under 6 years of age unless advised by a clinician, and patients with severe hypertension or cardiovascular disease without medical supervision.